I'm seeing activity and potential for cheap buying in GNVC and CURN today, for those that care.
Slightly OT: Observing that another way to play TWTI is through EBIO, a consumables company that Trickle holds and which is not a BLUE H play:
>>MADISON, Wis. and REDMOND, Wash., Oct. 10 /PRNewswire/ -- Third Wave Technologies, Inc. and Epoch Biosciences, formerly Epoch Pharmaceuticals, Inc. (Nasdaq: EBIO) announced today they have entered into a development, licensing and supply agreement under which Epoch will develop, license and supply certain of its proprietary technologies for Third Wave's Invader® operating system for genetic analysis. The addition of Epoch's technologies has the capacity to significantly increase the throughput and enhance the performance of Third Wave's Invader operating system.
As part of the agreement, Epoch will provide access to certain of its fluorescent dye chemistries to Third Wave for incorporation into its Invader assays. Third Wave will fund certain development activities at Epoch and will also have an option to license Epoch's proprietary minor groove binder and modified base technologies.
The Invader technology can be used for detection of SNPs (single nucleotide polymorphisms) and other mutations, quantification of gene expression and viral loads and testing for drug resistant infectious diseases, providing a flexible platform technology with a wide breadth of applications for clinical and research applications.
``This is an ideal example of how our technologies can be applied to today's leading methods of genetic analysis,'' commented Bill Gerber, CEO of Epoch. ``We look forward to a mutually productive relationship with Third Wave, and anticipate a positive response to our combined technologies from Third Wave customers.''
Under the agreement, Epoch will receive licensing payments, as well as royalties based on sales.
Epoch Biosciences develops proprietary products with commercial applications in the fields of genomics and molecular diagnostics, including the detection of inherited diseases and single nucleotide polymorphisms to identify individuals at risk for disease or adverse drug reactions. Epoch believes that its technologies can be adapted to genetic analysis systems in use and being developed by others. Information about the company, including reports and other information filed by Epoch with the Securities and Exchange Commission, is available on the worldwide web at epochbio.com or by phoning 425-821-7535.
Third Wave develops and provides DNA and RNA analysis technologies for use in genome research, pharmacogenomics and clinical applications. <<
EBIO is a reagent company that ought to be relatively immune to the capex slowdown and FDA wackiness that has hampered some biotechs and tool companies of late. It also has ties to ABI and PKI. It rides with good company, in one of the less cyclical trickle niches. Small & cheap, but's it been cheaper.
Cheers, Tuck |
